Introduction
============

Ovarian cancer is one of the most commonly diagnosed malignant tumors that threaten the health of women. A total of 22,240 new cases and 14,030 deaths were reported in the United States in 2013 [@B1]. Chemotherapy is an adjunctive therapy for ovarian cancer patients treated with surgery. Doxorubicin (DOX), also known as adriamycin (ADR), is an anthracycline antibiotic that is widely used as a chemotherapeutic agent for the treatment of a variety of solid tumors, including ovarian cancer [@B2]. Previously reported anticancer effects of DOX include DNA intercalation, which interferes with the biosynthesis of macromolecules; inhibition of topoisomerase II enzyme activity, which initializes DNA damage; increased production of reactive oxygen species (ROS) and direct membrane effects [@B3], [@B4]. Despite the extensive and long-standing clinical application of DOX in cancer treatment, cancer cells always develop resistance to this drug. Once tumor cells develop drug resistance, they become resistant not only to the drug used but also to a broad range of structurally and functionally unrelated compounds. This phenomenon, known as multidrug resistance (MDR) [@B5], is a major obstacle towards the successful treatment of ovarian cancer and is the main cause of the failure of chemotherapy.

To date, several mechanisms, such as increased efflux of drugs out of cancer cells to reduce the uptake of drug into cells through ATP-dependent pump P-glycoproteins [@B5], have been proposed to explain MDR. However, MDR is a multifactorial process which involves altered expression of many proteins; therefore, proteomic approaches are well-suited for investigating the mechanisms of MDR [@B6]-[@B8]. Recently, it has been suggested that the resistance of tumor cells to anticancer drugs is related to the capacity of cells to escape apoptosis [@B9], [@B10], and mitochondria is the \'housekeeper\' of cell apoptosis, thus it is rational to apply quantitative proteomics [@B11] to systematically analyze the differentially expressed proteins in the mitochondria of drug-resistant tumor cells. Doxorubicin-resistant cell line NCI_ADR/RES is a cell line derived from OVCAR8 ovarian cancer cell line by continuous *in vitro* exposure to increasing concentrations of doxorubicin. NCI_ADR/RES shows resistance not only to doxorubicin itself, but also to a broad range of structurally and functionally unrelated compounds, and is thus considered as a good model for studying the mechanism of drug-induced acquired resistance. Our studies showed that other than change of mitochondrial protein expression, mitochondrial morphology, localization and activity were also greatly altered in drug-resistant NCI_ADR/RES cells, indicating that mitochondria could be potential therapeutic targets of doxorubicin resistance in ovarian cancer cells.

Materials and methods
=====================

Cell culture and SILAC labeling
-------------------------------

The human ovarian tumor cell line OVCAR8 and its doxorubicin resistant subline NCI_ADR/RES were gifts from Dr. Nouri Neamati of the University of Southern California. OVCAR8 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator with 5% CO~2~ at 37°C. Culture conditions for NCI_ADR/RES cells were identical with OVCAR8 cells except that the concentration of L-glutamine was 5 mM. Cell culture media were changed every two days.

For forward SILAC labeling, OVCAR8 cells were grown in RPMI 1640 medium supplemented with "light" amino acids (L-\[^12^C~6~,^14^N~4~\]-arginine (Arg0) and L-\[^12^C~6~,^14^N~2~\]-lysine (Lys0)), and NCI_ADR/RES cells were cultured in 1640 medium supplemented with "heavy" amino acids(L-\[^13^C~6~,^15^N~4~\]-arginine (Arg10) and L-\[^13^C~6~,^15^N~2~\]-lysine (Lys8). For reverse labeling, the OVCAR8 cells were grown in "heavy" SILAC medium, and NCI_ADR/RES cells were grown in "light" SILAC medium. For SILAC cell culture, cells were grown in SILAC medium supplemented with 10% heat-inactivated dialyzed fetal bovine serum (Invitrogen, Carlsbad, CA), streptomycin and penicillin for at least six cell population-doubling times to achieve complete isotope incorporation(\>97%).Media used for SILAC labeling were renewed every two days.

Measurement of doxorubicin resistance by MTT analysis in OVCAR8 and NCI_ADR/RES cells
-------------------------------------------------------------------------------------

The toxicity of doxorubicin to OVCAR8 and NCI_ADR/RES cells was determined with an MTT assay. All studies were performed with triplicate samples and repeated at least three times. Briefly, cells were harvested by trypsinization, resuspended in RPMI1640 medium, and plated in a 96-well plate at 3,000 cells per well. The culture medium was replaced 48 h after treatment with different doses of doxorubicin (ranging from 0.1 nM to 100 μM), and 50 μL of 1.0 mg/ml sterile filtered 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT; Sigma) was added to each well. Unreacted dye was removed after 4 h and insoluble formazan crystals were dissolved in 150 µl of DMSO. Absorbance at 570 nm (reference wavelength: 630 nm) was measured with a Synergy 2 multi-mode microplate reader (BioTek, Winooski, VT).

Purification of mitochondria
----------------------------

For mitochondria isolation from SILAC labeled cells, equal number of two types of cells grown in light or heavy SILAC media were combined and mitochondria were isolated by Nycodenz density gradient centrifugation as described previously [@B12], [@B13].

Validation of mitochondrial purity by western blot
--------------------------------------------------

The purity of isolated mitochondria was assessed with western blot against marker proteins from different cellular compartments as described previously [@B13].

In-solution digestion
---------------------

In-solution digestion of SILAC-labeled mitochondrial proteins was performed as described previously with slight modifications [@B14]. Briefly, 100 μg of protein mixture was reduced and alkylated before Lys-C was added and digested at 37°C for 6 h. After diluting the concentration of urea to 1 M with 25 mM NH~4~HCO~3~, sequence grade trypsin (Promega, Madison, WI) was added at an enzyme/protein ratio of 1:50 and digested at 37°C overnight. Digestion was stopped by adding formic acidto a final concentration of 0.1%. The digested peptide mixture was centrifuged at 13,000g for 10 min and the resulting supernatant was collected for MS analysis.

2D-LC-MS/MS analysis for protein identification and quantification
------------------------------------------------------------------

2D-LC-MS/MS analysis was performed using an Eksigent HPLC system (Dublin, C, USA) interfaced to an LTQ-Orbitrap XL (Thermo Fisher Scientific, Waltham, USA) equipped with an in-house built nanoelectrospray device as described previously [@B13].

For a single analysis, 100 μg of peptide mixtures were pressure loaded onto a 2D silica capillary column (200 μm id) packed with 3 cm of C~18~resin (sunchrom 5μ, Friedrichsdorf, Germany) and 3 cm of strong cation exchange resin (Luna 5μ, SCX 100A, Phenomenex, USA) . The buffer solutions used and salt elution gradients were identical as described previously [@B13].

Data processing and bioinformatics analysis
-------------------------------------------

SILAC-based quantification was conducted using MaxQuant (version 1.2.2.5) [@B15] against UniportKB human database (downloaded on November 28, 2012) with 131,282 entries to which 175 commonly observed contaminants and all the reverse sequences were added. Carbamidomethylation was set as a fixed modification. Variable modifications included oxidation of methionine residues and N-terminal protein acetylation. Full tryptic specificity was required. Up to three missed cleavage and three labeled amino acids (arginine and lysine) were allowed. The minimum required peptide length was set to six amino acids. The initial precursor and fragment ion maximum mass tolerance in the database search were set to 10 ppm and 0.5 Da, respectively. To pass statistical evaluation, the false discovery rate (FDR) for both the peptides and proteins were set to 0.01 to ensure a maximum of 1% false identification hits. Proteins with at least two peptides (with one unique peptide) were considered as valid identifications**.**

UniprotKB database and bioinformatic tool Panther [@B16] were used for functional annotation to interpret the relationship between protein expression and the molecular mechanisms of doxorubicin resistance in ovarian cancer cells. Cellular localization of the differentially expressed proteins was annotated with UniprotKB database.

RNA extraction and quantitative real-time RT-PCR
------------------------------------------------

RNA of the OVCAR8 or NCI_ADR/RES cells was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) following the product manual. The concentration of RNA was determined by measuringthe absorbance at 260nm in Nanodrop(Thermo Fisher Scientific), and the quality was examined by the ratio of absorbance at 260-280 nm. Then RNA was reverse transcribed into cDNA with Promega A5000 Reverse Transcription System (Promega, Madison, WI) according to the manufacturer\'s protocol. Quantitative real-time RT-PCR analysis was performed on Bio-Rad CFX real-time PCR detection system (Bio-rad) using SYBR Green detection kit (Applied Biosystems) according to the manufacturer\'s instructions. The specific primers for MDR1 were 5\'-GGGAGCTTAACACCCGACTTA-3\' (sense) and 5\'-GCCAAAATCACAAGGGTTAGCTT-3\'(antisense), for Sirt4 were 5\'-CCGTAGAGCTGTGAGAGAATGAA-3\'(sense) and 5\'-AGGGTCCAGAGGAGGACTTG -3\'(antisense), for PCCA were 5\'-AAGCTACCTCAACATGGATGC-3\' (sense) and 5\'-GTGTCAGGTCCAATGAAAACGA-3\'(antisense), for Foxred1 were 5\'-CTCAGTAGGTGGGATTTGTCAGC-3\' (sense) and 5\'-CTCTGCACTTTCACGTTGCTC-3\' (antisense), and for GAPDH were 5\'-CTTCACCACCATGGAGGAGGC-3\' (sense) and 5\'-GGCATGGACTGTGGTCATGAG-3\' (antisense). The relative quantification of gene expression was analyzed by the 2^-ΔΔCT^ method. Real-time quantitative RT-PCR analysis was repeated at least three times.

Western blot to validate SILAC results
--------------------------------------

Proteins were extracted from OVCAR8 and NCI_ADR/RES cells as described previously [@B14] and protein concentration was determined with Bradford method. The protein samples (20 μg) were separated by SDS-PAGE and electro-transferred to PVDF membranes, which were then probed with indicated primary antibodies after blocked with 5% non-fat milk. The protein bands were visualized with enhanced chemiluminescence substrate after probed with indicated secondary antibodies. All of the western blot analyses were repeated three times and GAPDH was used as loading control.

siRNA design, construction and transfection
-------------------------------------------

The siRNA against TOP1MT was synthesized by Gene Pharma (Shanghai, China). Three target sequences was synthesis: 5\'-GAGGAUGUUAGAUCAUGAATT-3\' and 5\'-UUCAUGAUCUAACAUCCUCTT-3\' (siRNA1), 5\'-CCCUGUAUUUCAUCGAUAATT-3\' and 5\'-UUAUCGAUGAAAUACAGGGTT-3\' (siRNA2), 5\'-GGCAGGAGAAGACUUUGAATT-3\' and 5\'-UUCAAAGUCUUCUCCUGCCTT-3\' (siRNA3), sequences which do not match any known human coding sequence were used for negative control against TOP1MT. Transfection was mediated with Lipofectamine 2000 transfection reagent according to the manufacturer\'s instruction. Briefly, OVCAR8 or NCI_ADR/RES cells were plated into 24-well plates at the density of 1.1\*10^5^ cells/well or 1.3\*10^5^ cells/well, respectively. When the cells were 40-50% confluence, they were transfected with 100 nmol/L of specific siRNAs or control siRNA after a pre-incubation for 20 min with Lipofectamine 2000 diluted in Opti-MEM. After 6 hours of transfection, the medium was replaced with normal cell culture medium. 72 hours after transfection, cell proteins were harvested and protein concentration was measured with Brandford method. The efficiency of siRNA knockdown was monitored with immunoblotting by using primary antibody against TOP1MT.

Measurement of the cell proliferative activity
----------------------------------------------

As knockdown efficiency for TOP1MT siRNA2 is much more effective, measurement of cell proliferative activity was carried out following transfection of TOP1MT siRNA2 or control siRNA with the cell counting kit‑8 (CCK8; Dojindo, Tokyo, Japan). Briefly, OVCAR8 or NCI_ADR/RES cells were transfected as described above, then the transfected cells were plated into 96-well plates and cultured for 24 hours before incubated with different concentrations of doxorubicin. After treatment of doxorubicin for 48 hour, CCK8 solution was added 2 hour before the end of incubation. Cell viability was measured with a spectrophotometer at an absorbance of 450 nm. The inhibition rates of cell growth were calculated according to the formula: inhibition rate (%) = (1-mean absorbance of treatment group/mean absorbance of untreatment group) ×100%. Results shown are representative of three separate experiments.

Observation of mitochondrial morphology with transmission electron microscopy
-----------------------------------------------------------------------------

OVCAR8 and NCI_ADR/RES cells were harvested by trypsinization, washed twice with PBS and fixed in 2.5% glutaraldehyde in PBS (pH 7.4) at room temperature for 30 min, then post-fixed with 1% osmium tetroxide in 0.1 M sodium cacodylate for 1 hour. Following dehydration in a graded series of acetone (2 hour each at 30, 50, 70, 80, 90and 100%), cell pellets were embedded in Embed 812 and sliced into 70 nm sections using a Leica ultramicrotome EM UC6 (Leica, Germany). After staining with uranyl acetate and lead citrate, sections were observed under a Spirit 120 kV transmission electron microscope (FEI, the Netherlands).

Observation of mitochondria with Mitotracker Green staining
-----------------------------------------------------------

OVCAR8 and NCI_ADR/RES cells were seeded in 35 mm Petri dishes, after reaching 50-70% confluence, the cells were stained with 50 nM Mitotracker Green (Molecular probes Invitrogen) diluted in the corresponding culture media for 20 min at 37°C. After incubation, cells were washed twice with PBS. A few microliters of PBS were added before the coverslip was put in place to prevent cell drying. Cell images were obtained with an Olympus FV1000 laser scanning confocal microscope under visible light or under fluorescence excitation at 520 nm.

Observation of mitochondrial localization with immunofluorescence microscopy
----------------------------------------------------------------------------

The localization of mitochondria was further assayed by immunofluorescence microscopy. OVCAR8 and NCI_ADR/RES cells were grown on 35 mm Petri dishes and fixed with 4% formaldehyde in PBS at room temperature for 15 min. Cells were permeabilized with 0.2% (v/v)Triton-X100 in PBS at room temperature for 10 min and blocked for 30min atroom temperature with PBS containing 5% BSA. After incubation with primary antibodies against mitochondrial ATP synthase β (ab14730,Abcam) in 0.05%Tritonatroom temperature for 2 hours, cells were washed three times with PBS, and then incubated withCF™488A fluorescent antibodies (Biotium) for 1hour. After wash three times with PBS, DAPI (Beyotime, China) was used to stain the cell nuclei. Cell images were obtained with an Olympus FV1000 laser scanning confocalmicroscope.

Mitochondrial membrane potential (∆Ψm) analysis with Rhodamine B
----------------------------------------------------------------

∆Ψm was measured with the fluorescent probe Rhodamine B (Sigma) as described by Reungpatthanaphong and coworkers [@B17]. Briefly, OVCAR8 and NCI_ADR/RES cells were collected by trypsinization and incubated with 50 nM Rhodamine B dissolved in serum-free culture medium at 37°C for 30 min and then washed twice with PBS and suspended in culture medium. Fluorescence was read with a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) at 488 nm excitation and 580 nm emission. Approximately 10^5^ cells were analyzed for each cell.

Results and discussion
======================

Although the mechanisms of DOX-induced MDR in cancer cells have been widely explored, the exact reason for drug resistance has not been fully understood. Here, we systematically analyzed the differentially expressed proteins in the mitochondria of OVCAR8 and its DOX-resistant cell line NCI_ADR/RES with quantitative proteomics and mass spectrometry. NCI_ADR/RES cells, which were originally thought to be derived from a MCF-7 breast cancer cell line, were later identified to be derived from OVCAR8 ovarian adenocarcinoma cells [@B18]. NCI_ADR/RES is a multidrug resistance cell line, as shown in [Additional file 3](#SM3){ref-type="supplementary-material"}: supplementary Figure S1, treatment with doxorubicin produced marked inhibition of cell proliferation in OVCAR8 cells as determined by MTT assays, with an IC~50~ value of 24.1 nM at 48 hours after treatment. NCI_ADR/RES cells showed significant resistance to DOX with an IC~50~ value of 2.85 µM, which was more than 100 times higher than that of OVCAR8 cells.

Differential protein expression in the mitochondria of OVCAR8 and NCI_ADR/RES cells
-----------------------------------------------------------------------------------

As mitochondria play a central role in cell life and death, we anticipate that mitochondria play important roles in the MDR of cancer cells, thus comparative mitochondrial proteome was performed to systematically analyze the protein expression in the mitochondria. Western blot results showed that mitochondrial proteins were greatly enriched in the purified samples ([Additional file 3](#SM3){ref-type="supplementary-material"}: supplementary Figure S2).

To obtain reliable quantification results, we conducted SILAC experiments in triplicates, including one forward and two reverse labeling experiments ([Additional file 3](#SM3){ref-type="supplementary-material"}: supplementary Figure S3 depicts the flowchart for quantitative mitochondrial proteome). 2D-LC-MS/MS analysis allowed for the quantification of 1696, 1697 and 1667 proteins in one forwards and two reverse SILAC experiments, respectively. 63% of the proteins were quantified in all the three replicates, and nearly 80% proteins were quantified at least twice in the three replicates ([Additional file 3](#SM3){ref-type="supplementary-material"}: supplementary Figure S4), implying a good level of reproducibility in MS analysis. A total of 2085 proteins were quantified in this study ([Additional file 1](#SM1){ref-type="supplementary-material"}: supplementary Table S1). To improve the reliability of the quantification results, only the proteins quantified at least twice of SILAC labeling experiments were considered for further functional analysis. Since expression level of the majority of proteins were unchanged, and the mean value of the proteins quantified more than twice is 1.14, and SD value is 0.20, thus two-fold was chosen as threshold for significant changes of protein expression. With these criteria, the expression of 122 proteins was changed in the mitochondria of NCI_ADR/RES cells, including 40 proteins being down-regulated and 82 proteins being up-regulated in DOX-resistant NCI_ADR/RES cells ([Additional file 2](#SM2){ref-type="supplementary-material"}: Supplementary Table 2). 54 proteins annotated to be located in mitochondria in UniprotKB database was listed in Table [1](#T1){ref-type="table"}.

Validation of differential expressed proteins
---------------------------------------------

The differential expression levels of proteins quantified by SILAC approach were validated using real-time quantitative RT-PCR. Figure [2](#F2){ref-type="fig"}A shows relative mRNA expression levels of MDR1, PCCA, FOXRED1 and Sirt4 normalized against GAPDH. Compared with OVCAR8, NCI_ADR/RES cells have a marked up-regulation of MDR1, FOXRED1 and Sirt4, and a down-regulation of PCCA, which were identical with SILAC results. Figure [2](#F2){ref-type="fig"}B shows the western blot results of TOP1MT, HINT2 and HK1 expression in the two cell lines. Compared to OVCAR8 cells, the protein expression of TOP1MT and HINT2 were up-regulated in NCI_ADR/RES cells, whereas the expression of HK1 was down-regulated, which were consistent with SILAC quantification results.

Evaluation of the roles of TOP1MT on doxorubicin resistance in ovarian cancer using RNAi
----------------------------------------------------------------------------------------

SILAC results shown that TOP1MT are up-regulated in doxorubicin resistant NCI_ADR/RES cells compared to doxorubicin-sensitive OVCAR8 cells. Western bolt results also validated the SILAC results (Figure [2](#F2){ref-type="fig"}B). Then, we performed knockdown experiments in OVCAR8 and NCI_ADR/RES cells to evaluate the roles of TOP1MT in doxorubicin resistance. Three pairs of TOP1MT target siRNAs were selected to performed RNAi experiment and immunoblot analysis showed that siRNA 2 and siRNA 3 could conduct greater than 90% efficiency in the reduction of the protein level of TOP1MT in OVCAR8 cells and more than 80% efficiency in the reduction of the protein level of TOP1MT in NCI_ADR/RES cells when GAPDH was used as the internal standard (Figure [3](#F3){ref-type="fig"}A). Since siRNA2 is much more effective, it was chosen for further functional study. As shown in Figure [3](#F3){ref-type="fig"}B, no decreased viability in TOP1MT knockdown OVCAR8 cells, and 13% reduction in the viability of TOP1MT knockdown NCI_ADR/RES cells following treatment with indicated concentrations of doxorubicin compared to scramble siRNA transfected controls. This result clearly demonstrated that TOP1MT involved in MDR in ovarian cancer.

Functional classification of dysregulated mitochondrial proteins
----------------------------------------------------------------

The functional annotation of the dysregulated proteins with Uniprot and Panther revealed that most of these proteins are related to cell apoptosis, substance metabolism, cell adhesion, transport, detoxification and drug metabolism (Figure [1](#F1){ref-type="fig"}). Some of the key proteins that may contribute in part to DOX resistance in ovarian cancer cells are discussed below.

**Cell death** Since most anticancer agents exert anticancer effects through induction of apoptosis, the escape of apoptosis or increase of anti-apoptosis activities presents a key mechanism of acquired drug resistance in the cancer cells [@B10], [@B19]. Since mitochondria are critical "gatekeepers" to the apoptosis process, as expected, the expression levels of 15 mitochondrial proteins that play important roles in the apoptosis were changed in NCI_ADR/RES cells. P-gp1, the protein product of the MDR1 (multidrug resistance protein 1) gene, is responsible for pumping DOX out of the cells in an ATP-dependent manner to reduce the accumulation of DOX in cells, thus accounting partially for the mechanism of DOX resistance[@B20]. However, P-gp1 has also been identified to be expressed in the mitochondria and has a functional activity in the mitochondria of MDR cells [@B21]-[@B23]. Besides acting as drug pump, P-gp1 was also reported to protect resistant tumor cells from caspase-dependent apoptosis in the mitochondria [@B24], [@B25], thus accounting for drug-resistance. Here, qRT-PCR showed that the mRNA expression level of P-gp1was up-regulated by 240 fold (Figure [2](#F2){ref-type="fig"}A) and protein level of this protein was up-regulated by 24-fold (SILAC ratio = 24.2 ± 5.56) in NCI_ADR/RES cells. However, most previously published proteomic studies on DOX resistance didn\'t identify this 170 kD membrane protein due to the limitation of the 2-DE method used[@B8], [@B26], which is biased against membrane proteins and the extremely low and high molecular weight proteins.

SLK(STE20-related serine/threonine-protein kinase), a caspase 3-activated kinase, plays a role in the induction of apoptosis [@B27], [@B28], its expression was found to be down-regulated in NCI_ADR/RES cells. Hexokinase 1 (HK1), an important protein to coordinate glycolysis and oxidative phosphorylation, was also found to inhibit cell apoptosis by modulating Bax, Bak and Bad [@B29]. Here, its expression was down-regulated in NCI_ADR/RES cells (Figure [2](#F2){ref-type="fig"}B). However, histidine triad nucleotide-binding protein 2(HINT2), a mitochondrial apoptotic sensitizer [@B30], was up-regulated in DOX-resistant cells (Figure [2](#F2){ref-type="fig"}B).The exact mechanism for its up-regulation in DOX-resistant NCI_ADR/RES cells is still unknown. Collectively, dysregulated anti-apoptotic protein P-gp1and these apoptosis-related proteins might increase the antiapoptotic ability of NCI_ADR/RES cells, thus contribute to drug resistance.

**Substance metabolism**As mitochondria play a key role in substance metabolism, the expression of some proteins participating in metabolism including protein metabolism, nucleotide metabolism, amino acid metabolism and small molecular metabolism were changed in NCI_ADR/RES cells. In agreement with previous findings that DOX could affect fatty acid metabolism in the heart [@B2], the levels of several proteins participating in fatty acid beta-oxidation, including ABCD3,PCCB,PCCA, decreased in NCI_ADR/RES cells. As impairment of essential fatty acid metabolism plays a key role in DOX-induced damage in cultured rat cardiomyocytes [@B31], we speculate that down-regulation of these fatty acid metabolism related proteins may represent one aspect of DOX toxicity in NCI_ADR/RES cells.

**Detoxification and drug metabolism**One mechanism of MDR is that cancer cells up-regulate some DNA repair proteins, such as TOP1MT, UNG, and MTPOLB, to repair drug-induced damage, TOP1MT is a mitochondrial protein involved in mitochondrial DNA replication, and RNAi knockdown experiment demonstrated its involvement in doxorubicin resistance in NCI_ADR/RES cells (Figure [3](#F3){ref-type="fig"}). In addition, up-regulation of some drug-response proteins, such as xenobiotic metabolizing protein EPHX1 and doxorubicin metabolic enzyme CBR4, could also protect NCI_ADR/RES cells from drug insults. DOX treatment may cause adaptive response through the mitochondrial antioxidant defense system and detoxification enzymes, thus potentially contribute to the occurrence of multidrug resistance.

Besides that, DOX also affect the expression of some mitochondrial enzymes involved in respiration and oxidative phosphorylation, such as ND2, CYBA, ETFDH, SURF1, ATP11, and SDH5. However, some key components of oxidative phosphorylation kept unchanged in NCI_ADR/RES cells (supplementary table 1), indicating that mitochondrial participation in DOX resistance is not related with mitochondrial energy production, but rather its role in cell apoptosis.

Several mitochondrial proteomic studies have been performed to screen for doxorubicin-resistant biomarkers of cancer. Strong *et al.* investigated mitochondrial proteome alterations in ADR/verapamil resistant MCF-7 breast cancer cells (MCF-7/ADRVp) with 2-DE and MS, and found that the abundance of 13 proteins was changed in the soluble mitochondrial fraction of MCF-7/ADRVp cells [@B32]. Although both MCF-7/ADRVp and NCI_ADR/RES cells showed resistance to DOX, the expression patterns of several proteins were different in these two types of drug resistant cells. Expression levels of cofilin, trifunctional enzyme subunit alpha and isoform 1 of 3,2-trans-enoyl-CoA isomerase were found to be up-regulated in MCF-7/ADRVp cells but were unchanged in NCI_ADR/RES cells. Jiang *et al.* investigated alterations in the mitochondrial proteome of Raji cells treated with ADR using 2D-DIGE and LTQ-MS/MS, and found altered expression of 37 proteins [@B33], some of which do not agree with the findings for MCF-7/ADRVp or NCI_ADR/RES. For example, PHB, which was up-regulated in DOX-treated Raji cells, was virtually unaltered in NCI_ADR/RES cells. The different origins of the cell lines may account for these differences.

Mitochondrial morphology observation with electron microscopy (EM)
------------------------------------------------------------------

Besides changes of mitochondrial protein expression, mitochondrial morphology and its architecture were further observed with EM. Most of mitochondria in OVCAR8 cells were rod-like and elongated in shape and the cristae were regularly distributed (Figure [4](#F4){ref-type="fig"}A, A1), while those in NCI/ADR-RES cells were mainly round and swollen, with some vacuolation in the cristae (Figure [4](#F4){ref-type="fig"}B, B1). These observations are in agreement with previous studies on mitochondria in the human breast carcinoma MCF-7 cell line and its derived multidrug-resistant subline MCF-7/DX [@B34] and DOX-treated HepG2 cells [@B35]. Since mitochondrial swelling and vacuolation are signs of impaired mitochondrial function that ultimately result in mitochondrial energy deficit, mitochondrial impairment may be one of the underlying mechanisms accounting for DOX-induced MDR in ovarian cancer.

Mitochondrial localization observation and mitochondrial membrane potential analysis
------------------------------------------------------------------------------------

To investigate the localization of mitochondria in OVCAR8 and NCI_ADR/RES cells, mitochondria were stained with two different techniques: immunofluorescence (IF) and Mitotracker Green staining. With IF observation, mitochondria are crowded around the nucleus and spread toward the cell periphery with strong fluorescencein OVCAR8 cells, whereas the mitochondria are evenly distributed through the cytoplasm with weaker fluorescence in the drug-resistant NCI_ADR/RES cells (Figure [5](#F5){ref-type="fig"}A).

With Mitotracker Green staining, similar situation was observed in OVCAR8 cells with IF, however, mitochondria are only observed in the subplasmalemmal regions but not in the cytoplasm in NCI_ADR/RES cells (Figure [5](#F5){ref-type="fig"}B). The different findings in the NCI_ADR/RES cells may be related with the differences on these two methods in detecting mitochondria: Mitotracker Green staining of mitochondria is dependent on mitochondrial membrane potential (MMP), while IF detection of mitochondria is independent of MMP. Based on the different observations of mitochondria with IF and Mitotracker Green staining in NCI_ADR/RES cells, we speculate that there are two populations of mitochondria present in resistant NCI_ADR/RES cells: active peripheral mitochondria with MMP and central mitochondria with noMMP. Similar observations were reported in resistant MCF-7/DX cells[@B34].Cells adjust the localization of mitochondria to meet different functional needs: the role of peripheral mitochondria is to produce ATP for cell motility and secretion and to regulate calcium concentration at the plasma membrane [@B36], [@B37], while central mitochondria are involved in calcium signaling in the ER and in the cell apoptosis pathway[@B38], [@B39].The two populations of mitochondria in the NCI_ADR/RES cells may thus have different roles: peripheral mitochondria supply ATP for cell detoxification and cell motility, and central mitochondria with no MMP could interfere with the cell apoptosis and contribute to drug resistance. Consistent with this speculation, mitochondrial membrane potential (MMP, ΔΨm) measured with Rhodamine B was greatly decreased in NCI/ADR-RES cells (Figure [5](#F5){ref-type="fig"}C). As ΔΨm is essential for mitochondrial function, decreased ΔΨm indicate that NCI/ADR-RES cells have impaired mitochondrial functions.

In all, important mitochondrial protein expression, mitochondrial morphology, localization and activities were changed in NCI_ADR/RES cells, supporting the connection between mitochondrial activity and cell resistance to chemotherapeutic agents, indicating that the impairment of mitochondria plays an important role in DOX resistance in NCI_ADR/RES cells and mitochondria would be considered as therapeutic targets for cancer chemotherapy.

Conclusions
===========

In this study, the SILAC-based quantitative proteomic strategy was applied to study protein changes in the mitochondria of OVCAR8 and its doxorubicin-resistant NCI_ADR/RES cells. Our results demonstrate that the expression of some proteins participating in cell apoptosis was changed in NCI_ADR/RES cells, indicating increased antiapoptotic activities in resistant cells. Further analysis showed that mitochondrial morphology, localization and mitochondrial membrane potential were greatly changed in doxorubicin-resistant NCI_ADR/RES cells, confirming that mitochondrial function is impaired in NCI_ADR/RES cells. All these results indicate that mitochondria play an important role in doxorubicin resistance in ovarian cancer cells and mitochondria could be novel therapeutic targets for overcoming drug resistance in ovarian and other human cancers.
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![Functional annotation of dysregulated proteins in the mitochondria of NCI_ADR/RES cells as compared to OVCAR8 cells.](thnov04p1164g001){#F1}

![Validate SILAC results with qRT-PCR and western blot **A**: Relative mRNA expression levels of Sirt4, PCCA, FOXRED1, MDR1 after normalization with GAPDH mRNA levels as determined by qRT-PCR. **B**: Western blot analysis of TOP1MT, HINT2 and HK1 expression in the two cell lines.](thnov04p1164g002){#F2}

![Evaluation of the role of TOP1MT on doxorubicin resistance in OVCAR8 and NCI_ADR/RES cells using siRNA knockdown **A**:Western blot analysis shown that transfection of OVCAR8 and NCI_ADR/RES cells with three pairs of TOP1MT siRNAs significantly reduced TOP1MT levels, whereas TOP1MT protein level was not significantly suppressed by control siRNA and Lipofectamine 2000(Blank control). **B**: CCK8 assay shown that transfection of NCI_ADR/RES cells with TOP1MT siRNA 2 reduced the cell viability following treatment with indicated concentrations of doxorubicin compared to sracmble siRNA transfected controls, whereas it has no effect in OVCAR8 cells.](thnov04p1164g003){#F3}

![Ultrastructure of OVCAR8 and NCI_ADR/RES cells shown by electron microscopy. (A) Overview of the ultrastucture of OVCAR 8 cells. A1 and A2are the enlarged images of the selected areas of (A). Arrows: rod-like mitochondria with complete cristae. (B) Overview of the ultrastructure of NCI_ADR/RES cells. B1 and B2 are the enlarged images of the selected areas of (B). Arrows: Swollen mitochondria with vacuolation in the cristae.](thnov04p1164g004){#F4}

![Analysis of mitochondrial function **A:**Immunofluorescence observation of mitochondria localization. The mitochondria of OVCAR8 cells and NCI_ADR/RES cells were detected with mitochondrial ATP synthase β antibody and CF™488A labeled fluorescent secondary antibody (green). Nuclei were stained with DAPI (blue). Magnification: all images 1200×. **B**: Fluorescence images of Mitotracker Green staining in OVCAR8and NCI_ADR/RES cells. Mitochondria in the cells were stained with 50 nM Mitotracker Green for 20 min and observed under a confocal microscope. **C:** Mitochondria membrane potential analysis in OVCAR8 and NCI_ADR/RES cells. Cells were stained with 50 nM Rhodamine B for 30 min and analyzed with a flow cytometer.](thnov04p1164g005){#F5}

###### 

Differentially expressed mitochondrial protein\* between OVCAR8 and NCI_ADR/RES cells quantified by SILAC.

  --------------------------------------------------------------------------------------------------------------------------------
  Accession   Gene name   Protein name                                                                      SILAC ratio\
                                                                                                            (NCI_ADR/RES/OVCAR8)
  ----------- ----------- --------------------------------------------------------------------------------- ----------------------
  P08183      MDR1        ATP-binding cassette, sub-family B (MDR/TAP), member 1                            24.16±5.56

  Q9BZF9      UACA        Uvealautoantigen with coiled-coil domains and ankyrin repeats                     2.46±0.72

  Q9UQ90      SPG7        Spastic paraplegia 7 protein                                                      2.18±0.37

  Q9BX68      HINT2       Histidine triad nucleotide-binding protein 2, mitochondrial                       2.04±0.26

  P30536      MBR         Mitochondrial benzodiazepine receptor                                             2.41±0.60

  Q13232      NME3        Nucleoside diphosphate kinase 3                                                   2.17±0.06

  P30048      PRDX3       Thioredoxin-dependent peroxide reductase, mitochondrial                           0.50±0.04

  P19367      HK1         Hexokinase-1                                                                      0.42±0.02

  Q969M1      TOMM40B     Mitochondrial import receptor subunit TOM40B                                      2.89±1.05

  Q6NUK1      SCAMC1      Mitochondrial ATP-Mg/Pi carrier protein 1                                         0.42±0.01

  E7FJF3      GDAP1       Ganglioside-induced differentiation-associated protein 1                          2.55±0.89

  Q8N4T8      CBR4        Quinone reductase CBR4                                                            2.51±0.05

  Q969P6      TOP1MT      DNA topoisomerase I, mitochondrial                                                2.32±0.36

  P13051      UNG         Uracil-DNA glycosylase                                                            2.06±0.63

  Q9UHN1      MTPOLB      DNA polymerase subunit gamma-2, mitochondrial                                     2.00±0.53

  P55809      OXCT1       Succinyl-CoA:3-ketoacid-coenzyme A transferase 1                                  0.48±0.04

  Q5ST30      VARS2       Valyl-tRNAsynthetase, mitochondrial                                               2.50±0.60

  Q9HA77      CARS2       Probable cysteinyl-tRNAsynthetase, mitochondrial                                  0.30±0.03

  Q9UIJ7      AK3         GTP:AMP phosphotransferase mitochondrial                                          2.58±0.22

  Q9Y6E7      SIRT4       NAD-dependent ADP-ribosyltransferase sirtuin-4                                    2.87±0.08

  O00746      NME4        Nucleoside diphosphate kinase, mitochondrial                                      2.19±0.24

  Q9UDR5      AASS        Alpha-aminoadipicsemialdehyde synthase, mitochondrial                             2.53±0.47

  P36957      DLST        2-oxoglutarate dehydrogenase complex component E2                                 2.48±1.20

  O14874      BCKDK       \[3-methyl-2-oxobutanoate dehydrogenase \[lipoamide\]\] kinase, mitochondrial     2.47±1.34

  P49419      ALDH6A1     Aldehyde dehydrogenase family 6 member A1                                         2.13±0.27

  Q9UKU7      ACAD8       Isobutyryl-CoA dehydrogenase, mitochondrial                                       2.04±0.26

  Q96H96      COQ2        Para-hydroxybenzoate\--polyprenyltransferase, mitochondrial                       2.08±1.05

  Q8NE62      CHDH        Choline dehydrogenase, mitochondrial                                              2.99±0.30

  O94925      GLS         Glutaminase kidney isoform, mitochondrial                                         2.02±0.13

  P30837      ALDH1B1     Aldehyde dehydrogenase X, mitochondrial                                           2.17±0.16

  Q9NUB1      ACAS2L      Acetyl-CoA synthetase 2                                                           2.05±0.94

  P45954      ACADSB      Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial               0.40±0.06

  Q9P2J9      PDP2        \[Pyruvate dehydrogenase \[acetyl-transferring\]\]-phosphatase 2, mitochondrial   0.44±0.04

  Q8IW45      CARKD       Carbohydrate kinase domain-containing protein                                     0.47±0.13

  A3KMH1      VWA8        von Willebrand factor A domain-containing protein 8                               0.45±0.05

  Q13423      NNT         NAD(P) transhydrogenase, mitochondrial                                            0.49±0.02

  Q13825      AUH         Methylglutaconyl-CoA hydratase, mitochondrial                                     0.19±0.06

  P05166      PCCB        Propionyl-CoA carboxylase beta chain, mitochondrial                               0.43±0.07

  P05165      PCCA        Propionyl-CoA carboxylase alpha chain, mitochondrial                              0.42±0.06

  P28288      ABCD3       ATP-binding cassette sub-family D member 3                                        0.40±0.03

  Q305V2      ND2         NADH-ubiquinone oxidoreductase chain 2                                            2.17±1.23

  P13498      CYBA        Cytochrome b(558) alpha chain                                                     2.07±1.46

  A7UNU5      ETFDH       Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial           2.05±0.18

  E5KRX5      SURF1       Surfeit locus protein 1                                                           2.44±0.77

  Q5TC12      ATP11       ATP synthase mitochondrial F1 complex assembly factor 1                           0.36±0.01

  Q9NX18      SDH5        Succinate dehydrogenase assembly factor 2, mitochondrial                          0.28±0.07

  P21980      TGM2        Protein-glutamine gamma-glutamyltransferase 2                                     2.51±0.55

  P17931      LGALS3      Galactose-specific lectin 3                                                       2.26±0.33

  Q96NE9      FRMD6       FERM domain-containing protein 6                                                  2.32±0.16

  Q86UT6      NLRX1       NLR family member X1                                                              4.02±0.16

  Q96CU9      FOXRED1     FAD-dependent oxidoreductase domain-containing protein 1                          2.83±0.56

  Q3MIX3      ADCK5       Uncharacterized aarF domain-containing protein kinase 5                           2.80±0.46

  Q53H82      LACTB2      Beta-lactamase-like protein 2                                                     2.20±0.16

  Q9GZT6      MDS025      Coiled-coil domain-containing protein 90B, mitochondrial                          2.07±0.38
  --------------------------------------------------------------------------------------------------------------------------------

\* Protein was annotated in Uniprot database as mitochondrial protein or to be located in mitochondria.
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